基因组学在个体化癌症治疗中的应用及其对中国早期药物开发的影响:来自第50届ASCO年会上美中抗癌协会(USCACA)第6届年会上的报告

Q Medicine

癌症 Pub Date : 2014-08-01 DOI:10.5732/cjc.014.10110

Wei Zhang, Shi-Yuan Cheng, Li-Fang Hou, Li Yan, Yun-Guang Tong

{"title":"基因组学在个体化癌症治疗中的应用及其对中国早期药物开发的影响:来自第50届ASCO年会上美中抗癌协会(USCACA)第6届年会上的报告","authors":"Wei Zhang, Shi-Yuan Cheng, Li-Fang Hou, Li Yan, Yun-Guang Tong","doi":"10.5732/cjc.014.10110","DOIUrl":null,"url":null,"abstract":"The 6th Annual Meeting of the United States Chinese Anti-Cancer Association (USCACA) was held in conjunction with the 50th Annual Meeting of American Society of Clinical Oncology (ASCO) on May 30, 2014 in Chicago, Illinois, the United States of America. With a focus on personalized medicine, the conference featured novel approaches to investigate genomic aberrations in cancer cells and innovative clinical trial designs to expedite cancer drug development in biomarker-defined patient populations. A panel discussion further provided in-depth advice on advancing development of personalized cancer medicines in China. The conference also summarized USCACA key initiatives and accomplishments, including two awards designated to recognize young investigators from China for their achievements and to support their training in the United States. As an effort to promote international collaboration, USCACA will team up with Chinese Society of Clinical Oncology (CSCO) to host a joint session on \"Breakthrough Cancer Medicines\" at the upcoming CSCO Annual Meeting on September 20th, 2014 in Xiamen, China. ","PeriodicalId":10034,"journal":{"name":"癌症","volume":"33 8","pages":"371-5"},"PeriodicalIF":0.0000,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/3c/cjc-33-08-371.PMC4135365.pdf","citationCount":"2","resultStr":"{\"title\":\"Genomics in personalized cancer medicine and its impact on early drug development in China: report from the 6th Annual Meeting of the US Chinese Anti-Cancer Association (USCACA) at the 50th ASCO Annual Meeting.\",\"authors\":\"Wei Zhang, Shi-Yuan Cheng, Li-Fang Hou, Li Yan, Yun-Guang Tong\",\"doi\":\"10.5732/cjc.014.10110\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The 6th Annual Meeting of the United States Chinese Anti-Cancer Association (USCACA) was held in conjunction with the 50th Annual Meeting of American Society of Clinical Oncology (ASCO) on May 30, 2014 in Chicago, Illinois, the United States of America. With a focus on personalized medicine, the conference featured novel approaches to investigate genomic aberrations in cancer cells and innovative clinical trial designs to expedite cancer drug development in biomarker-defined patient populations. A panel discussion further provided in-depth advice on advancing development of personalized cancer medicines in China. The conference also summarized USCACA key initiatives and accomplishments, including two awards designated to recognize young investigators from China for their achievements and to support their training in the United States. As an effort to promote international collaboration, USCACA will team up with Chinese Society of Clinical Oncology (CSCO) to host a joint session on \\\"Breakthrough Cancer Medicines\\\" at the upcoming CSCO Annual Meeting on September 20th, 2014 in Xiamen, China. \",\"PeriodicalId\":10034,\"journal\":{\"name\":\"癌症\",\"volume\":\"33 8\",\"pages\":\"371-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/3c/cjc-33-08-371.PMC4135365.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"癌症\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5732/cjc.014.10110\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"癌症","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5732/cjc.014.10110","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

摘要

2014年5月30日，美国华人抗癌协会(USCACA)第六届年会暨美国临床肿瘤学会(ASCO)第50届年会在美国伊利诺伊州芝加哥市召开。会议重点关注个性化医疗，重点介绍了研究癌细胞基因组畸变的新方法和创新的临床试验设计，以加快生物标志物定义的患者群体的癌症药物开发。小组讨论进一步就推进中国个体化癌症药物的发展提供了深入的建议。会议还总结了USCACA的主要举措和成就，包括设立两个奖项，表彰中国的年轻研究人员取得的成就，并支持他们在美国接受培训。为促进国际合作，USCACA将与中国临床肿瘤学会(CSCO)合作，在即将于2014年9月20日在中国厦门举行的CSCO年会上共同举办“癌症药物突破”专题会议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Genomics in personalized cancer medicine and its impact on early drug development in China: report from the 6th Annual Meeting of the US Chinese Anti-Cancer Association (USCACA) at the 50th ASCO Annual Meeting.

查看原文本刊更多论文

The 6th Annual Meeting of the United States Chinese Anti-Cancer Association (USCACA) was held in conjunction with the 50th Annual Meeting of American Society of Clinical Oncology (ASCO) on May 30, 2014 in Chicago, Illinois, the United States of America. With a focus on personalized medicine, the conference featured novel approaches to investigate genomic aberrations in cancer cells and innovative clinical trial designs to expedite cancer drug development in biomarker-defined patient populations. A panel discussion further provided in-depth advice on advancing development of personalized cancer medicines in China. The conference also summarized USCACA key initiatives and accomplishments, including two awards designated to recognize young investigators from China for their achievements and to support their training in the United States. As an effort to promote international collaboration, USCACA will team up with Chinese Society of Clinical Oncology (CSCO) to host a joint session on "Breakthrough Cancer Medicines" at the upcoming CSCO Annual Meeting on September 20th, 2014 in Xiamen, China.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

癌症 ONCOLOGY-

CiteScore

3.47

自引率

0.00%

发文量

9010

审稿时长

12 weeks

期刊介绍： In July 2008, Landes Bioscience and Sun Yat-sen University Cancer Center began co-publishing the international, English-language version of AI ZHENG or the Chinese Journal of Cancer (CJC). CJC publishes original research, reviews, extra views, perspectives, supplements, and spotlights in all areas of cancer research. The primary criteria for publication in CJC are originality, outstanding scientific merit, and general interest. The Editorial Board is composed of members from around the world, who will strive to maintain the highest standards for excellence in order to generate a valuable resource for an international readership.